Data / New clinical trials / Lymphoma, Follicular

Lymphoma, Follicular trials: 175 new since Nov 2024

Name: New Lymphoma, Follicular clinical trials
Creator: SpecStream
License: https://creativecommons.org/licenses/by/4.0/

The full list. New Lymphoma, Follicular clinical trials: 175 rows for $8.75, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. The list gains about 5 rows a month. The new rows come each week by email, $19 a month.

Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The weekly rows run until you cancel, from the link in each delivery. The rows on this page are a sample.

For agents and scripts: this list is ordered at https://specstream.ai/data/clinical-trials/condition/lymphoma-follicular, and every list with its row count and price is at https://specstream.ai/data/lists.json.

Updated October 23, 2026. Source: ClinicalTrials.gov API v2 (U.S. National Library of Medicine).

175 clinical studies in Lymphoma, Follicular were first posted on ClinicalTrials.gov from November 15, 2024 to October 23, 2026; 52 have an industry sponsor and 125 are recruiting or about to. The newest, NCT07893197, was posted on October 23, 2026: Ceritinib Treatment for Recurrent Meningiomas (Kevin Petrecca).

The request: Every new Lymphoma, Follicular clinical trial on ClinicalTrials.gov, with the sponsor, phase, sites and the listed contact. $10 of credit on sign-up, no card.

Get new trials like these Watch a sponsor

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

175New trials
52Industry sponsored
125Recruiting or not yet
October 23, 2026Latest posted

Newest trials

The newest 100 of 175, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

First posted	NCT ID	Title	Sponsor	Phase	Status	Conditions	Enrollment	Countries	Source
October 23, 2026	NCT07893197	Ceritinib Treatment for Recurrent Meningiomas	Kevin Petrecca	Phase 2	Not yet recruiting	Recurrent Meningioma, Grade I and Grade II	10	Canada	clinicaltrials.gov
October 22, 2026	NCT07888647	IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas	German Cancer Research Center	Phase 2	Not yet recruiting	Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4	216	Germany	clinicaltrials.gov
October 20, 2026	NCT07883941	Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid...	GUSTAVO SALGUERO	Phase 1	Not yet recruiting	Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies, Diffuse Large B Cell Lymphoma...	12		clinicaltrials.gov
October 15, 2026	NCT07875413	Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell...	AbelZeta Inc.	Phase 2	Not yet recruiting	Large B Cell Lymphoma, LBCL, Diffuse Large B Cell Lymphoma (DLBCL), Relapse Diffuse Large B Cell Lymphoma, High Grade B...	55	United States	clinicaltrials.gov
October 13, 2026	NCT07869797	Real-world Study of the Effectiveness and Tolerability of Outpatient Titration of OxyContin for the Moderate and Severe Pain in Cancer...	Mundipharma (China) Pharmaceutical Co. Ltd	Observational	Not yet recruiting	Cancer Pain	378	China	clinicaltrials.gov
October 1, 2026	NCT07853040	A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment	Incyte Corporation	Phase 1	Not yet recruiting	Hepatic Insufficiency, Liver Diseases	24		clinicaltrials.gov
September 28, 2026	NCT07844967	A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of HS-10506	Jiangsu Hansoh Pharmaceutical Co., Ltd.	Phase 1	Recruiting	Hepatic Impairment (Moderate or Mild) & Normal Hepatic Function	32	China	clinicaltrials.gov
September 28, 2026	NCT07844811	Early Redox Biomarker Changes After Stellate Ganglion Block in Traumatic Brain Injury	University Medical Centre Ljubljana	Observational	Completed	Brain Injuries, Traumatic	20	Slovenia	clinicaltrials.gov
September 22, 2026	NCT07834931	PMCF Study Fortilink-TC Ti	BAAT Medical Products B.V.	Observational	Recruiting	Degenerative Disc Disease Lumbar, Spondylolisthesis, Grade 1	50	Spain	clinicaltrials.gov
September 22, 2026	NCT07834736	PMCF Study Fortilink-TS Ti	BAAT Medical Products B.V.	Observational	Recruiting	Degenerative Disc Disease Lumbar, Spondylolisthesis, Grade 1	50	Spain	clinicaltrials.gov
September 18, 2026	NCT07828730	Sparrow App Guided Evaluation (SAGE) Vanguard Trial for Aortic Stenosis in Adults Aged Seventy and Older	Sunnybrook Health Sciences Centre	Not applicable	Not yet recruiting	Moderate or Severe Aortic Stenosis	1,000		clinicaltrials.gov
August 25, 2026	NCT07783594	Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma	M.D. Anderson Cancer Center	Phase 2	Not yet recruiting	Randomized, Phase 2, Epcoritamab, Watch & Wait, Untreated, Tumor Burden, Follicular Lymphoma	40	United States	clinicaltrials.gov
August 21, 2026	NCT07780097	TRTME: Improving Outpatient Initiation of Medication for Opioid Use Disorder Following Hospitalization	T. John Winhusen, PhD	Not applicable	Enrolling by invitation	Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe	30	United States	clinicaltrials.gov
August 7, 2026	NCT07752056	Low-Sodium Diet for Postpartum Blood Pressure Control	Women and Infants Hospital of Rhode Island	Not applicable	Not yet recruiting	Hypertensive Disorder of Pregnancy, Pre-Eclampsia, Severe, Pre-Eclampsia; Mild, Postpartum	110		clinicaltrials.gov
August 6, 2026	NCT07750886	Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)	Natera, Inc.	Observational	Recruiting	Non-Hodgkin Lymphoma, T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma, Primary Mediastinal...	200	United States	clinicaltrials.gov
August 5, 2026	NCT07747792	Shorter Treatment Regimen Implementation Evaluation Study	Centre for Infectious Disease Research in Zambia	Observational	Completed	Tuberculosis (TB), Tuberculosis in Children, Tuberculosis Treatment Effectiveness, Tuberculosis Active	175	Zambia	clinicaltrials.gov
July 30, 2026	NCT07736950	A Study Comparing a New Drug (Surovatamig) With Standard Radiotherapy With or Without Rituximab in Adults With Limited Stage Nodal...	Australasian Leukaemia and Lymphoma Group	Phase 3	Not yet recruiting	Follicular Lymphoma	140		clinicaltrials.gov
July 28, 2026	NCT07731789	Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma	University of Washington	Phase 2	Recruiting	Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma	30	United States	clinicaltrials.gov
July 22, 2026	NCT07719855	A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide...	Ruijin Hospital	Phase 3	Not yet recruiting	Follicular Lymphoma ( FL)	652	China	clinicaltrials.gov
July 9, 2026	NCT07691606	A Study of ARC-02 in B-cell NHL	Taiho Oncology, Inc.	Phase 1	Recruiting	B-cell Non Hodgkin Lymphoma	140	Australia, France, Italy, Poland, Spain, United States	clinicaltrials.gov
June 29, 2026	NCT07673666	GliomaAI-Astro23: MRI-Based Detection of IDH Mutant Astrocytoma (Grade 2 and 3)	Deep Learning Institute of Radiological Sciences	Observational	Completed	Glioma, Glioma (Diagnosis), Astrocytoma, Astrocytoma of Brain, Astrocytoma, Grade II, Astrocytoma, IDH-Mutant, Grade 2...	1,372	India	clinicaltrials.gov
June 26, 2026	NCT07671248	Tirzepatide in the Treatment of Cannabis Use Disorder	McMaster University	Phase 3	Not yet recruiting	Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe	15	Canada	clinicaltrials.gov
June 24, 2026	NCT07664787	Safety and Efficacy of Renal Denervation for Untreated Grade I Hypertension: a Pilot Study	Ruijin Hospital	Not applicable	Not yet recruiting	Hypertension, Grade 1	20		clinicaltrials.gov
June 17, 2026	NCT07653386	Clinical Trial of an Ointment in Patients With Mild and Moderate Atopic Dermatitis	VinUniversity	Not applicable	Completed	Mild and Moderate Atopic Dermatitis Patients, Atopic Dermatitis (AD)	90	Vietnam	clinicaltrials.gov
June 10, 2026	NCT07638982	Axatilimab + CAR-T for High-Risk Lymphoma	Northside Hospital, Inc.	Phase 1	Not yet recruiting	Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell...	29	United States	clinicaltrials.gov
June 8, 2026	NCT07634471	A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)	Merck Sharp & Dohme LLC	Phase 2/3	Recruiting	Follicular Lymphoma	960	Argentina, Australia, Chile, China, Greece, Israel, Italy, Poland, South Korea...	clinicaltrials.gov
June 8, 2026	NCT07631598	Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses	Montefiore Medical Center	Not applicable	Recruiting	Opioid Use Disorder, Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate	512	United States	clinicaltrials.gov
June 5, 2026	NCT07630545	A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.	Mission Therapeutics	Phase 1	Recruiting	Parkinson's Disease (PD), Mild to Moderate Parkinson's Disease, Early Stage Parkinson's Disease	106	Australia, France, Germany, United Kingdom	clinicaltrials.gov
May 27, 2026	NCT07609862	A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies	Guangzhou Lupeng Pharmaceutical Company LTD.	Phase 1/2	Recruiting	Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Waldenström...	92	China	clinicaltrials.gov
May 27, 2026	NCT07609446	Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma	The First Affiliated Hospital of Soochow University	Observational	Not yet recruiting	Indolent Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Mantle Cell Lymphoma	30	China	clinicaltrials.gov
May 20, 2026	NCT07599033	Effects of a Progressive Adapted Physical Education Program on Muscular Strength and Endurance in Adolescents With Mild Intellectual...	Inonu University	Not applicable	Completed	Intellectual Disability, Mild, Muscular Strength	46	Turkey (Türkiye)	clinicaltrials.gov
May 19, 2026	NCT07596186	Predict Early Cognitive Changes in a Healthy Elderly Population by Passively Recording Sensor Data From Mobile Devices	Soroka University Medical Center	Observational	Active not recruiting	Cognitive Decline, Mild	98	Israel	clinicaltrials.gov
May 18, 2026	NCT07592481	Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors	Centre Hospitalier de la côte Basque	Not applicable	Not yet recruiting	Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma ( FL), Waldenstrom Macroglobulinaemia, Lymphoplasmacytic...	40		clinicaltrials.gov
May 14, 2026	NCT07586722	Effects of a 12-Week Pickleball Training Program on Cognitive and Motor Skills in Adolescents With Mild Intellectual Disability	Elif Top	Not applicable	Active not recruiting	Intellectual Disability, Mild	32	Turkey (Türkiye)	clinicaltrials.gov
May 14, 2026	NCT07585851	Administration of Repurposed Ketoconazole in Glioma Patients	Universitas Padjadjaran	Early phase 1	Active not recruiting	Diffuse Glioma, Diffuse Glioma, Grade I, Diffuse Glioma, Grade II, Diffuse Glioma, Grade III, Diffuse Glioma, Grade IV	80	Indonesia	clinicaltrials.gov
May 14, 2026	NCT07585747	A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide	Institute of Hematology & Blood Diseases Hospital, China	Phase 2	Not yet recruiting	Follicular Lymphoma	27	China	clinicaltrials.gov
May 1, 2026	NCT07562022	A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular...	Sinocelltech Ltd.	Phase 3	Recruiting	Follicular Lymphoma (FL)	93	China	clinicaltrials.gov
April 30, 2026	NCT07559474	A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe...	Incyte Corporation	Phase 1	Recruiting	Hepatic Insufficiency, Liver Diseases	16	United States	clinicaltrials.gov
April 30, 2026	NCT07558538	A Single Dose, Dose Escalation Clinical Trial on the Safety, Tolerability and Efficacy of Lyophilized Powder for Inhalation of Recombinant...	Shanghai Zhongshan Hospital	Early phase 1	Recruiting	ARDS (Moderate or Severe), ARDS (Acute Respiratory Distress Syndrome)	24	China	clinicaltrials.gov
April 29, 2026	NCT07555470	Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	Phase 2	Recruiting	Follicular Lymphoma	80	China	clinicaltrials.gov
April 24, 2026	NCT07550855	Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma	Sun Yat-sen University	Phase 2	Not yet recruiting	Follicular Lymphoma (FL)	52	China	clinicaltrials.gov
April 24, 2026	NCT07550634	Pharmacokinetics and Safety of MDR-001 in Mild and Moderate Hepatic Impairment	MindRank AI Ltd	Phase 1	Not yet recruiting	Hepatic Impairment (Mild and Moderate, Child-Pugh Class A and B), Hepatic Insufficiency (MeSH ID: D048550)	32	China	clinicaltrials.gov
April 23, 2026	NCT07548697	A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non...	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Early phase 1	Recruiting	B-cell Non Hodgkin Lymphoma (NHL), DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma (FL)	24	China	clinicaltrials.gov
April 23, 2026	NCT07546760	A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234	AstraZeneca	Phase 1	Recruiting	Hepatic Impairment	28	United States	clinicaltrials.gov
April 22, 2026	NCT07545603	Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma	Evopoint Biosciences Inc.	Phase 2	Recruiting	Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, Follicular Lymphoma, Grade 3, Follicular Lymphoma Grade 3A	65	China	clinicaltrials.gov
April 15, 2026	NCT07530952	Green VR for Depression	Sykehuset Innlandet HF	Not applicable	Completed	Depression, Mild or Moderate	45	Norway	clinicaltrials.gov
April 14, 2026	NCT07528781	Novel 3-dimensional Echocardiographic Quantification of Mitral Regurgitant Volume	Germans Trias i Pujol Hospital	Observational	Recruiting	Moderate or Severe Mitral Regurgitation	200	Spain	clinicaltrials.gov
April 9, 2026	NCT07519772	A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)	Merck Sharp & Dohme LLC	Phase 1/2	Recruiting	Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse	280	Argentina, Australia, Brazil, Canada, Chile, China, France, Germany, Israel...	clinicaltrials.gov
April 1, 2026	NCT07505849	ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma	KeshuZhou	Phase 2	Not yet recruiting	Follicular Lymphomas	100		clinicaltrials.gov
March 30, 2026	NCT07502118	NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)	Health Institutes of Turkey	Phase 2/3	Recruiting	Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma, Diffuse...	40	Turkey (Türkiye)	clinicaltrials.gov
March 24, 2026	NCT07490925	Transpulmonary Pressure-guided Mechanical Ventilation Strategy in Right Ventricular Protection in Patients With ARDS	Beijing Chao Yang Hospital	Not applicable	Recruiting	ARDS (Moderate or Severe)	180	China	clinicaltrials.gov
March 17, 2026	NCT07476378	A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Not applicable	Not yet recruiting	Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Follicular, Lymphoma, Mantle-Cell, Chronic Lymphocytic Leukemia...	69	China	clinicaltrials.gov
March 12, 2026	NCT07468136	Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas	Mayo Clinic	Phase 1/2	Recruiting	Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Diffuse Astrocytoma...	33	United States	clinicaltrials.gov
March 5, 2026	NCT07451197	Family-Focused Study to Support Medication for Opioid Use Disorder	University of Wisconsin, Madison	Not applicable	Not yet recruiting	Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe	338	United States	clinicaltrials.gov
February 20, 2026	NCT07424833	A Study of APG-3288 in Relapsed/Refractory Blood Cancers	Ascentage Pharma Group Inc.	Phase 1	Recruiting	Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic...	180	China, United States	clinicaltrials.gov
February 20, 2026	NCT07422610	Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment	Novartis Pharmaceuticals	Phase 1	Recruiting	Advanced Malignancies and Hepatic Impairment	24	France, Italy, Spain, United Kingdom	clinicaltrials.gov
February 19, 2026	NCT07420062	Reduced Dosage and/or Visitation Protocol for the Treatment of Acute Malnutrition in Kenya	International Food Policy Research Institute	Not applicable	Not yet recruiting	Acute Malnutrition in Childhood, Acute Malnutrition, Severe, Acute Malnutrition, Moderate, Wasting	2,274	Kenya	clinicaltrials.gov
February 18, 2026	NCT07418190	Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular...	The First Affiliated Hospital with Nanjing Medical University	Phase 2	Recruiting	Relapsed/Refractory Follicular Lymphoma	33	China	clinicaltrials.gov
February 17, 2026	NCT07412405	This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells...	GUSTAVO SALGUERO	Not applicable	Not yet recruiting	Adult B-cell Acute Lymphoblastic Leukemia, Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell...	12		clinicaltrials.gov
February 13, 2026	NCT07410494	Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors	Essen Biotech	Phase 1/2	Recruiting	Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic), Prostate...	85	China	clinicaltrials.gov
February 13, 2026	NCT07410052	Microbiome-Targeted Enhancement of Neurocognition With Probiotics-Riboflavin Combination	Center for Health Sciences, Serbia	Not applicable	Not yet recruiting	Cognitive Deficits, Mild	28		clinicaltrials.gov
January 29, 2026	NCT07375407	Aerobic Exercise vs Physiological Ischemic Training in Stage 2 Hypertension	Universitas Padjadjaran	Not applicable	Completed	Primary Hypertension, Grade 2	60	Indonesia	clinicaltrials.gov
January 27, 2026	NCT07368764	The Suitability of Tience® for Treating Acne Scars	Linio Biotech Oy	Not applicable	Active not recruiting	Acne, Acne Scars	20	Finland	clinicaltrials.gov
January 22, 2026	NCT07360912	Haemorrhoidectomy With vs Without Lateral Internal Sphincterotomy	University of Baghdad	Not applicable	Completed	Grade III and IV Hemorrhoids	120	Iraq	clinicaltrials.gov
January 22, 2026	NCT07360288	Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma	TICAROS Co., Ltd.	Phase 2	Not yet recruiting	Follicular Lymphoma (FL)	40		clinicaltrials.gov
January 21, 2026	NCT07355283	IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular...	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	Phase 3	Not yet recruiting	Relapsed/Refractory Follicular Lymphoma	198	China	clinicaltrials.gov
January 15, 2026	NCT07345377	Study on Treatment Mechanisms and Efficacy Prediction of Individualized Transcranial Magnetic Stimulation in Adults With Irritable Bowel...	The Affiliated Hospital of Hangzhou Normal University	Not applicable	Enrolling by invitation	Irritable Bowel Syndrome (IBS), Pain, Depressive Disorder, Major, Moderate	160	China	clinicaltrials.gov
January 15, 2026	NCT07343934	huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma	University of Pennsylvania	Phase 1	Recruiting	Relapsed or Refractory Follicular Lymphoma	6	United States	clinicaltrials.gov
January 12, 2026	NCT07334873	Effect of Inhaled Nitric Oxide Therapy in Adults With Moderate-to-Severe Acute Respiratory Distress Syndrome	Nanfang Hospital, Southern Medical University	Not applicable	Not yet recruiting	ARDS (Moderate or Severe)	536	China	clinicaltrials.gov
January 8, 2026	NCT07328035	Remission in Adults With Severe Asthma in Thailand	Thammasat University	Observational	Recruiting	Severe Asthma, Asthma Control Level	230	Thailand	clinicaltrials.gov
December 23, 2025	NCT07299149	Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	Phase 2	Recruiting	Follicular Lymphoma	34	China	clinicaltrials.gov
December 18, 2025	NCT07291986	To Compare the Clinical Outcomes of FemtoLASIK and ICL Implantation in Treating Moderate Myopia Focusing on Refractive Stability, Contrast...	Walid Osama Abdel Rahman Nour El Din	Not applicable	Completed	Myopia, Moderate	60	Egypt	clinicaltrials.gov
December 15, 2025	NCT07282548	Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies	Ipsen	Observational	Withdrawn	Follicular Lymphoma	0		clinicaltrials.gov
December 12, 2025	NCT07278921	Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of...	Andrés José Maria Ferreri	Observational	Recruiting	Relapsed/Refractory Follicular Lymphoma	25	Italy	clinicaltrials.gov
December 8, 2025	NCT07270146	Effectiveness and Safety of Guilu Erxian Oral Liquid in the Treatment of Oligozoospermia and Asthenospermia With Syndrome of Shen (Kidney)...	DongE E Jiao Coporation Limited	Phase 4	Completed	Mild and Moderate Oligozoospermia Asthenospermia or Oligoasthenospermia and the Syndrome Differentiation Type is Shen...	360	China	clinicaltrials.gov
December 4, 2025	NCT07263490	PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)	Copenhagen University Hospital, Hvidovre	Observational	Recruiting	Pre-eclampsia, Oocyte Donation, Pre-Eclampsia; Complicating Pregnancy, Pre-Eclampsia; Mild, Pre-Eclampsia, Severe...	462	Denmark	clinicaltrials.gov
December 1, 2025	NCT07256015	Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy	Bristol-Myers Squibb	Observational	Active not recruiting	Psoriasis	200	Italy	clinicaltrials.gov
November 25, 2025	NCT07249905	Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma	ModeX Therapeutics, An OPKO Health Company	Phase 1/2	Recruiting	Lymphoma, Waldenström Macroglobulinemia (WM), DLBCL - Diffuse Large B Cell Lymphoma, PMBCL, HGBCL, FL Lymphoma...	180	Australia, Israel, Spain	clinicaltrials.gov
November 12, 2025	NCT07226843	A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers	Eli Lilly and Company	Phase 1	Recruiting	Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma	460	France, Germany, Italy, Japan, Poland, Spain, United Kingdom, United States	clinicaltrials.gov
November 6, 2025	NCT07225439	Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin...	Paolo Caimi, MD	Phase 1	Recruiting	Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary...	15	United States	clinicaltrials.gov
October 14, 2025	NCT07215910	Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer	Alliance for Clinical Trials in Oncology	Phase 3	Recruiting	Astrocytoma, IDH-Mutant, Grade 3	408	United States	clinicaltrials.gov
October 3, 2025	NCT07206121	Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery	Innoblative Designs, Inc.	Not applicable	Recruiting	Breast Cancer, Breast-conserving Surgery, Breast Cancer - Infiltrating Ductal Carcinoma, ER/PR+Her2neu, Grade I, II, III	10	United States	clinicaltrials.gov
October 2, 2025	NCT07203781	PEEP-induced Effects on Respiratory dRivE and EFfort	Radboud University Medical Center	Not applicable	Recruiting	ARDS (Moderate or Severe), Acute Hypoxemic Respiratory Failure	20	Netherlands	clinicaltrials.gov
September 29, 2025	NCT07197307	Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	Universität Münster	Phase 2	Recruiting	Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3B	120	Germany	clinicaltrials.gov
September 24, 2025	NCT07191249	Trial to Evaluate Efficacy and Safety of Subcutaneous Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma .	Tel-Aviv Sourasky Medical Center	Phase 2	Recruiting	Follicular Lymphoma	40	Israel	clinicaltrials.gov
September 24, 2025	NCT07189806	Longitudinal Phenotyping and Endotyping Study in Adult Patients With Mild, Moderate, or Severe Asthma	Hvivo	Observational	Recruiting	Asthma (Diagnosis)	250	United Kingdom	clinicaltrials.gov
September 23, 2025	NCT07187960	Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular...	Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.	Phase 3	Not yet recruiting	Follicular Lymphoma	228	China	clinicaltrials.gov
September 22, 2025	NCT07186959	EGPSS for Weight Management in an in Vivo Human Model	Liu Yan	Not applicable	Enrolling by invitation	Obesity, Mild	15	China	clinicaltrials.gov
September 16, 2025	NCT07176624	The PRE-VAIL Study	The First Hospital of Jilin University	Not applicable	Recruiting	ARDS (Moderate or Severe), Prone Position, Enteral Nutrition Feeding, Intensive Care Unit (ICU) Admission	259	China	clinicaltrials.gov
September 15, 2025	NCT07173790	Watch and Wait or Worry and Wait in Indolent Lymphoma	Seoul National University Hospital	Observational	Enrolling by invitation	Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma(MZL), Follicular...	250	South Korea	clinicaltrials.gov
September 11, 2025	NCT07168486	CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas	University of Maryland, Baltimore	Phase 1	Enrolling by invitation	B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), Follicular...	15	United States	clinicaltrials.gov
September 11, 2025	NCT07168291	Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma	First Affiliated Hospital Xi'an Jiaotong University	Early phase 1	Not yet recruiting	Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Burkitt Lymphoma	3	China	clinicaltrials.gov
September 11, 2025	NCT07167862	Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound	University of California, Irvine	Phase 4	Recruiting	Preeclampsia, Preeclampsia Postpartum, Preeclampsia Severe or Mild	96	United States	clinicaltrials.gov
September 4, 2025	NCT07154901	Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)	AstraZeneca	Phase 1	Completed	Renal Impairment	35	United States	clinicaltrials.gov
September 4, 2025	NCT07154823	A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies	Tempus AI	Observational	Recruiting	Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL)	550	United States	clinicaltrials.gov
August 19, 2025	NCT07128641	Odronextamab in Low Tumor Volume Advanced FL	Gottfried von Keudell, MD PhD	Phase 2	Recruiting	Follicular Lymphoma, Lymphoma	35	United States	clinicaltrials.gov
August 17, 2025	NCT07126678	Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma	The First Affiliated Hospital with Nanjing Medical University	Not applicable	Recruiting	Follicular Lymphoma, Treatment Naive	15	China	clinicaltrials.gov
August 14, 2025	NCT07123311	Implementation and Evaluation of an Internet-Based Stress Management Program for Health Students in the Sfax Region	University of Sfax	Not applicable	Completed	Anxiety Depression (Mild or Not Persistent)	148	Tunisia	clinicaltrials.gov
August 14, 2025	NCT07121946	This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma	LTZ Therapeutics, Inc.	Phase 1	Recruiting	Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma (MCL)...	42	United States	clinicaltrials.gov
August 11, 2025	NCT07114939	FTT PET/CT in Pancreatic Neuroendocrine Tumors	Abramson Cancer Center at Penn Medicine	Phase 1	Recruiting	Neuroendocrine Carcinoma Metastatic, Pancreatic Tumors	12	United States	clinicaltrials.gov

Sponsors posting most

Sponsor	New trials	Latest
University of Washington	3	July 28, 2026
Institute of Hematology & Blood Diseases Hospital, China	3	May 14, 2026
Sun Yat-sen University	3	April 24, 2026
AstraZeneca	3	April 23, 2026
Mayo Clinic	3	March 12, 2026
Novartis Pharmaceuticals	3	February 20, 2026
GUSTAVO SALGUERO	2	October 20, 2026
Incyte Corporation	2	October 1, 2026
BAAT Medical Products B.V.	2	September 22, 2026
Ruijin Hospital	2	July 22, 2026
Merck Sharp & Dohme LLC	2	June 8, 2026
Universitas Padjadjaran	2	May 14, 2026
Beijing Chao Yang Hospital	2	March 24, 2026
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	2	March 17, 2026
The First Affiliated Hospital with Nanjing Medical University	2	February 18, 2026
Eli Lilly and Company	2	November 12, 2025
Jacobs University Bremen gGmbH	2	July 29, 2025
Tianjin Medical University Cancer Institute and Hospital	2	June 22, 2025
GenomeFrontier Therapeutics TW Co., Ltd.	2	May 22, 2025
University of Nottingham	2	April 18, 2025

By phase

Phase	New trials	Latest
Not applicable	55	September 18, 2026
Observational	37	October 13, 2026
Phase 2	29	October 23, 2026
Phase 1	28	October 20, 2026
Phase 3	12	July 30, 2026
Phase 1/2	5	May 27, 2026
Early phase 1	4	May 14, 2026
Phase 4	3	December 8, 2025
Phase 2/3	2	June 8, 2026

By country

Country	New trials	Latest
United States	51	October 15, 2026
China	45	October 13, 2026
Spain	17	September 22, 2026
Italy	16	July 9, 2026
France	12	July 9, 2026
United Kingdom	12	June 5, 2026
Germany	11	October 22, 2026
Canada	9	October 23, 2026
Australia	9	July 9, 2026
Turkey (Türkiye)	9	June 8, 2026
Poland	8	July 9, 2026
South Korea	7	June 8, 2026
Israel	6	June 8, 2026
Greece	5	June 8, 2026
Taiwan	4	June 8, 2026
Egypt	4	December 18, 2025
Netherlands	4	October 2, 2025
Sweden	4	June 19, 2025
India	3	June 29, 2026
Argentina	3	June 8, 2026
Chile	3	June 8, 2026
Norway	3	April 15, 2026
Japan	3	November 12, 2025
Indonesia	2	May 14, 2026
Brazil	2	April 9, 2026

Where the register publishes

U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.